Mirvetuximab for folate-receptor–positive endometrial cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This Phase 2 study tests mirvetuximab (a targeted antibody drug) in women whose endometrial cancer is positive for folate receptor-alpha. It aims to shrink tumors and improve outcomes, especially in cancer that has returned or kept growing after previous treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your endometrial cancer is proven by scans (CT/MRI) to be persistent or recurrent
- Your tumor type and grade must match specific kinds (serous, carcinosarcoma with certain features, grade 2–3 adenocarcinoma, or clear cell)
- Your tumor must test positive for folate receptor-alpha (FRα) using the study’s testing rules
- You have at least one measurable tumor spot that doctors can track on scans
- You’ve had 0–3 prior treatment “lines” for the recurrent cancer (hormone therapy doesn’t count as a line)
- Your health tests are adequate (blood counts, liver, kidney) and you can do daily activities (ECOG 0–1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (PF-08634404) combined with chemotherapy for women with advanced or recurrent endometrial cancer that is MMR-proficient. The goal is to see if this combination works better than standard care.
This trial tests a drug called EV for people with recurrent endometrial cancer that has gotten worse after treatment. It may help if your cancer cells have a specific protein called nectin-4.
This Phase 1/2 study tests targeted drug(s) for endometrial cancer that has come back or never fully went away after prior treatments. You may be eligible if your tumor can be tested for specific biomarkers and your health allows treatment safely.
This trial tests whether adding a targeted therapy called fruquintinib (a type of anti-angiogenesis drug) to standard chemotherapy (paclitaxel and carboplatin) is more effective than chemotherapy alone for advanced or recurrent endometrial cancer that is not dMMR. If you haven't had prior systemic therapy for advanced disease and your tumor is pMMR, this could be an option.
This trial tests a combination of two investigational drugs—anlotinib (a capsule that blocks blood supply to tumors) and TQB2450 (an immunotherapy that helps your immune system attack cancer cells)—for people with recurrent or metastatic endometrial cancer that has not responded to previous platinum-based chemotherapy. The goal is to see if this combo can shrink tumors or slow their growth.
This trial tests a drug called mirvetuximab soravtansine for people with platinum-resistant ovarian, peritoneal, or fallopian tube cancer that has high levels of a protein called folate receptor-alpha (FRα). It is given through a vein (IV) and aims to stop cancer from growing.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.